Stock listing

NASDAQ:DMAC DiaMedica Therapeutics Inc. Stock

Home listing (NASDAQ) of DiaMedica Therapeutics Inc.

Follow DiaMedica Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:DMAC

$8.25 USD -0.34 (-4.0%)

Close on Nov 20, 2026

Past year +14.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$7.88 – $8.39 USDNov 20, 2026
Volume
313,537 sharesNov 20, 2026
Market cap
$445.1M USDAt the close on Nov 20, 2026 · price × 53.96M shares outstanding
52-week range
$5.25 – $11.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.66M USDMedian day 187,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
DiaMedica Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DMAC · Home$8.25 USD-0.34 (-4.0%)313,537$7.91$8.39$7.88$8.59Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DMAC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.25-0.34-4.0%$7.91$8.39$7.88313,537
$8.59+0.21+2.5%$8.40$8.91$8.40205,936
$8.38+0.05+0.6%$8.38$8.635$7.90294,961
$8.33-0.46-5.2%$8.65$9.305$8.27246,370
$8.79-0.54-5.8%$9.22$9.22$8.11214,091
$9.33-0.33-3.4%$9.53$9.59$9.05186,621
$9.66-0.01-0.1%$9.72$9.85$9.53139,358
$9.67+0.02+0.2%$9.645$9.86$9.21144,931
$9.65+0.29+3.1%$9.64$9.92$9.42144,642
$9.36+0.32+3.5%$9.10$9.739$9.055156,754
$9.04-1.73-16.1%$10.70$10.84$8.98330,456
$10.77+0.77+7.7%$10.15$11.00$10.15407,079
$10.00+0.71+7.6%$9.38$10.04$9.38302,393
$9.29+0.04+0.4%$9.47$9.505$8.96141,466
$9.25-0.27-2.8%$9.39$9.54$9.165174,646
$9.52-0.30-3.1%$9.83$9.985$9.42196,416
$9.82+1.13+13.0%$8.71$10.13$8.60519,652
$8.69-0.05-0.6%$8.72$8.72$8.30268,714
$8.74+0.02+0.2%$8.77$8.92$8.56129,603
$8.72+0.09+1.0%$8.55$8.79$8.29110,029
$8.63-0.06-0.7%$8.70$8.946$8.5187,987
$8.69+0.02+0.2%$8.72$8.95$8.59155,377
$8.67+0.80+10.2%$7.88$8.87$7.88168,169
$7.87+0.30+4.0%$7.78$7.99$7.60188,583
$7.57-0.47-5.8%$8.04$8.10$7.53260,800
$8.04+0.38+5.0%$7.82$8.24$7.66303,900
$7.66-0.16-2.0%$7.68$8.02$7.61287,000
$7.82-0.38-4.6%$8.21$8.21$7.72256,000
$8.20-0.13-1.6%$8.26$8.335$7.945185,600
$8.33+0.32+4.0%$8.00$8.45$8.00170,200
$8.01+0.02+0.3%$7.92$8.06$7.66240,300
$7.99-0.14-1.7%$8.01$8.415$7.95221,200
$8.13-0.29-3.4%$8.50$8.61$8.05242,300
$8.42+0.19+2.3%$8.23$8.63$8.19231,400
$8.23-0.12-1.4%$8.49$8.61$8.02335,700
$8.35+0.08+1.0%$8.33$8.54$8.10234,200
$8.27+0.07+0.9%$8.27$8.60$8.19219,100
$8.20-0.12-1.4%$8.30$8.381$8.03231,100
$8.32+0.38+4.8%$7.86$8.55$7.789362,800
$7.94+0.11+1.4%$7.85$8.00$7.44236,400
$7.83+0.27+3.6%$7.57$7.89$7.43209,200
$7.56-0.22-2.8%$7.70$7.75$7.34174,100
$7.78+0.52+7.2%$7.34$7.80$7.30312,100
$7.26+0.41+6.0%$6.86$7.35$6.825281,800
$6.850.000.0%$6.85$6.94$6.755195,000
$6.85+0.22+3.3%$6.75$7.00$6.675257,800
$6.63+0.10+1.5%$6.55$6.74$6.46187,300
$6.53-0.02-0.3%$6.55$6.65$6.36157,900
$6.55+0.08+1.2%$6.49$6.65$6.44145,600
$6.470.000.0%$6.57$6.877$6.33123,600
$6.47-0.12-1.8%$6.57$6.665$6.30182,400
$6.59+0.05+0.8%$6.50$6.974$6.50167,100
$6.54-0.21-3.1%$6.70$6.71$6.53119,100
$6.75+0.19+2.9%$6.56$6.887$6.49189,500
$6.56-0.19-2.8%$6.78$6.79$6.525116,100
$6.75+0.30+4.7%$6.60$6.935$6.59176,000
$6.45+0.10+1.6%$6.29$6.45$6.265145,900
$6.35-0.04-0.6%$6.44$6.59$6.22135,100
$6.39-0.36-5.3%$6.72$6.74$6.34116,500
$6.75+0.05+0.7%$6.68$6.80$6.56113,800
$6.70-0.04-0.6%$6.66$6.76$6.62118,300
$6.74+0.22+3.4%$6.60$6.865$6.60130,900
$6.520.000.0%$6.53$6.57$6.3284,700
$6.520.000.0%$6.58$6.73$6.5077,600
$6.52-0.29-4.3%$6.77$6.90$6.42130,900

Splits

1 split · NASDAQ:DMAC · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:DMAC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All DiaMedica Therapeutics Inc. news

DiaMedica Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 141 in all · newest Nov 12, 2026 · oldest 2019
Calls
25 calls with a replay · 25 with a transcript · latest Nov 13, 2026
Decks
14 decks · latest November 2026

Where DiaMedica Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:DMAC · Home listing · This pageNASDAQUnited StatesUSD
BOATS:DMACBOATSUnited StatesUSD

Valuation

Price/book 15.5× against a median of 2.4×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$410.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
15.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.67

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
DiaMedica Therapeutics Inc. · NASDAQ:DMACUS$445.1MUS$410.4Mn/an/an/a15.5×n/a0.0×1.67
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
G2GBIO, Inc. · KRX:456160US$449.1MUS$289.0Mn/a176×n/a4.3×−793.7%0.0×n/a
CytomX Therapeutics, Inc. · NASDAQ:CTMXUS$442.5MUS$98.96Mn/a7.0×n/a1.6×−609.0%0.0×1.21
Capricor Therapeutics, Inc. · NASDAQ:CAPRUS$441.3MUS$335.9Mn/an/an/a2.1×n/a0.4×0.94
Hansa Biopharma AB · OMXSTO:HNSAUS$440.9MUS$488.0Mn/a26.3×n/an/a−406.5%n/an/a
Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373US$439.3MUS$408.1Mn/a16.2×n/a19.4×−57.0%0.9×n/a
Clarity Pharmaceuticals Ltd. · ASX:CU6US$437.1MUS$239.0Mn/an/an/a3.5×n/a0.0×n/a
Hyundai Bioscience Co. Ltd. · KRX:048410US$435.2MUS$408.8Mn/a166×n/a5.7×−861.5%0.1×n/a
Oculis Holding AG · NASDAQ:OCSUS$434.8MUS$184.3Mn/a22,112×n/a1.8×n/a0.0×0.99
Median of the othersUS$441.1MUS$274.7M26.3×2.4×−507.7%0.0×1.00

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
15.50 USD · Analysts' mean
EPS, year to Dec 2026
-0.81 · 4 analysts

Team and board

Officers

OfficerRole
Rick PaulsPresident & CEO
Scott KellenChief Financial Officer
Ambarish ShahChief Technology Officer
Dominic CundariChief Commercial Officer
Julie KropChief Medical Officer

Board

DirectorRole
James ParsonsChairman of the Board
Charles SembaDirector
Daniel O’ConnorDirector
Michael GiuffreDirector
Richard KuntzDirector
Rick PaulsPresident & CEO
Tanya LewisDirector

Events

Calls

CallWhenStatus
DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2026 Earnings CallFri, Nov 13, 2026 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2026 Earnings CallTue, Aug 11, 2026 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2026 Earnings CallThu, May 07, 2026 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q4 2025 Earnings CallTue, Mar 31, 2026 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2025 Earnings CallThu, Nov 13, 2025 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2025 Earnings CallWed, Aug 13, 2025 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2025 Earnings CallWed, May 14, 2025 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2024 Earnings CallThu, Nov 14, 2024 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2024 Earnings CallThu, May 09, 2024 · 8:00 AM ETReplay
All 25 calls
CallWhenStatus
DiaMedica Therapeutics (NASDAQ:DMAC) Q4 2023 Earnings CallWed, Mar 20, 2024 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2023 Earnings CallTue, Nov 14, 2023 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2023 Earnings CallTue, Aug 15, 2023 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2023 Earnings CallTue, May 16, 2023 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q4 2022 Earnings CallWed, Mar 29, 2023 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2022 Earnings CallThu, Aug 11, 2022 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2022 Earnings CallThu, May 05, 2022 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q4 2021 Earnings CallTue, Mar 15, 2022 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2021 Earnings CallWed, Nov 10, 2021 · 7:00 PM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2021 Earnings CallThu, Aug 12, 2021 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2021 Earnings CallThu, May 06, 2021 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q4 2020 Earnings CallWed, Mar 10, 2021 · 7:00 PM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2020 Earnings CallThu, Nov 05, 2020 · 8:00 AM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2020 Earnings CallTue, Aug 11, 2020 · 8:00 PM ETReplay
DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2020 Earnings CallWed, May 13, 2020 · 8:00 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−5.8%
Q2 2026Aug 10, 2026 · After close+3.3%
Q1 2026May 6, 2026 · After close+0.1%
Q4 2025Mar 31, 2026−3.3%
Q3 2025Nov 12, 2025 · After close−14.1%
Q2 2025Aug 12, 2025 · After close+14.9%
Q1 2025May 13, 2025 · After close+0.5%
Q4 2024Mar 17, 2025 · Before open+3.8%
Q3 2024Nov 13, 2024 · After close−3.3%
Q2 2024Aug 7, 2024 · After close+3.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−6.3%
Q4 2023Mar 19, 2024 · After close−1.8%
Q3 2023Nov 13, 2023 · After close+6.8%
Q2 2023Aug 14, 2023 · After close+4.4%
Q1 2023May 15, 2023 · After close−10.8%
Q4 2022Mar 28, 2023 · After close−3.3%
Q3 2022Nov 9, 2022 · After close−1.6%
Q2 2022Aug 10, 2022 · After close+9.8%
Q1 2022May 4, 2022 · After close+2.8%
Q4 2021Mar 14, 2022 · After close−0.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck38 slidesNovember 2026
Investor Presentation (June 2026)Investor deck39 slidesJune 2026
Q4 2025 Earnings PresentationEarnings40 slidesMar 31, 2026
Q2 2025 Earnings PresentationEarnings46 slidesAug 13, 2025
Technical Presentation (July 2025)Technical21 slidesJul 17, 2025
Corporate Update (November 2024)Corporate update6 slidesNov 13, 2024
Investor Presentation (June 2024)Investor deck32 slidesJun 26, 2024
Technical Presentation (November 2023)Technical6 slidesNov 13, 2023
Investor Presentation (June 2023)Investor deck26 slidesJun 21, 2023
Corporate Update (May 2023)Corporate update6 slidesMay 22, 2023
All 14 decks
DeckKindSlidesDate
Investor Presentation (September 2021)Investor deck25 slidesSep 13, 2021
Corporate Update (June 2021)Corporate update15 slidesJun 29, 2021
Technical Presentation (May 2020)Technical26 slidesMay 13, 2020
Corporate Update (June 2019)Corporate update25 slidesJun 19, 2019

Open Decks

Financings

RaiseDate
Private placement of common shares
Closed: US$30.1M raised · US$3.5 a share
Buyers: Thomas von Koch (2,857,142 common shares through TomEnterprise Private AB for US$10,000,000; approximately 16.2% after closing); Trill AB (1,542,857 common shares for US$5,000,000; approximately 13.1% after closing); NFS/FMTC Roth IRA FBO Richard Jacinto II (400,000 common shares for US$1,400,000; approximately 9.6% after closing)
Insiders: Certain non-management related parties acquired an aggregate of $16.8 million or 4,799,999 common shares
Use of proceeds: To advance ongoing research and development activities
Jul 23, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$4.00 a share on Dec 6, 2018.

Price
US$4.00 a share
Shares offered
4,100,000 common shares
Offering size
US$16.4 million
Listing
DMAC on the Nasdaq Capital Market
Underwriter
Craig-Hallum Capital Group
Shares delivered
On or about Dec 11, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceAug 27, 2018
Filed publiclyNov 9, 2018
Amended 3 timesNewest Nov 28, 2018
Shares registered with an exchangeDec 3, 2018
Declared effective by the SECDec 6, 2018
Final prospectus, with the priceDec 10, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Dec 10, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000500.0K00
Cost of revenue39.0K30.0K25.0K24.0K21.0K21.0K04.00K2.21K
Gross profit-39.0K-30.0K-25.0K-24.0K-21.0K-21.0K500.0K-4.00K-2.21K
Research and development24.6M19.1M13.1M7.84M8.77M8.21M7.90M4.52M3.21M1.76M
Selling, general and administrative9.78M7.62M8.16M6.16M4.88M4.49M3.69M2.74M1.31M718.0K
Operating income-34.4M-26.7M-21.3M-14.0M-13.6M-12.7M-11.6M-6.76M-4.52M-2.48M
Depreciation and amortization43.0K39.0K30.0K25.0K24.0K21.0K21.0K15.0K4.00K2.21K
EBITDA-34.4M-26.6M-21.2M-14.0M-13.6M-12.7M-11.6M-6.75M-4.51M-2.48M
Interest expense353.0K82.0K229.0K119.0K0048.4K
Income before tax-32.7M-24.4M-19.3M-13.6M-13.6M-12.3M-10.6M-5.65M-4.26M-2.20M
Income tax28.0K30.0K43.0K28.0K28.0K27.0K31.0K80.0K-9.00K22.3K
Net income-32.8M-24.4M-19.4M-13.7M-13.6M-12.3M-10.6M-5.73M-4.26M-2.22M
Earnings per share, basic-0.70-0.60-0.60-0.52-0.65-0.78-0.89-0.74-0.72-0.47
Earnings per share, diluted-0.65-0.78-0.89-0.74-0.72

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents15.6M3.02M4.54M4.73M4.71M7.41M3.88M16.8M1.35M1.74M
Short-term investments44.2M41.1M48.4M28.8M40.4M20.1M4.00M000
Receivables258.0K236.0K369.0K82.0K130.0K340.0K823.0K780.0K80.0K52.0K
Inventory113.0K10.0K88.0K000
Current assets60.6M44.6M53.7M33.8M45.4M27.9M8.84M18.0M1.49M1.85M
Property, plant and equipment145.0K148.0K131.0K136.0K70.0K74.0K64.0K96.0K37.0K19.4K
Goodwill000
Total assets61.4M46.3M54.2M34.4M45.6M28.1M9.05M18.3M1.80M1.87M
Accounts payable1.48M940.0K926.0K734.0K509.0K1.10M182.0K483.0K513.0K250.0K
Current liabilities5.13M5.39M2.79M2.17M1.52M2.03M1.32M1.30M1.00M627.0K
Long-term debt000
Total debt240.0K340.0K400.0K469.0K52.0K118.0K178.0K23.0K200.5K
Total liabilities5.26M5.63M3.10M2.57M1.53M2.08M1.44M1.31M1.00M627.0K
Shareholders' equity56.1M40.7M51.1M31.8M44.0M26.0M7.62M17.0M799.0K1.25M
Shares outstanding53.7M42.8M38.0M26.4M26.4M18.7M12.0M12.0M6.37M4.74M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-29.1M-22.1M-18.7M-11.5M-12.3M-9.19M-9.10M-5.70M-3.90M-3.02M
Capital spending-40.0K-25.0K-24.0K-81.0K-22.0K-47.0K-2.00K-50.0K-22.0K-6.89K
Free cash flow-29.1M-22.1M-18.8M-11.6M-12.3M-9.23M-9.10M-5.75M-3.92M-3.03M
Cash from investing-2.19M8.56M-18.3M11.5M-20.5M-16.1M-3.91M-50.0K-22.0K-6.89K
Cash from financing43.9M12.0M36.8M-6.00K30.1M28.8M70.0K21.2M3.54M4.59M
Dividends paid000
Share buybacks28.9M75.0K21.2M3.54M4.59M
Change in cash12.6M-1.52M-185.0K21.0K-2.70M3.53M-12.9M15.5M-383.0K1.57M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 11, 2026Offer documentSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportMay 21, 2026Meeting outcomeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
ARS · Annual report to shareholdersApr 1, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 1, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 1, 2026Meeting noticeSEC
8-K · Current reportMar 30, 2026ResultsSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
8-K · Current reportJan 5, 2026Current reportSEC
8-K · Current reportDec 18, 2025Current reportSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
S-8 · Registration statement for employee plansNov 13, 2025Offer documentSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 3, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 15, 2025Big-stake noticeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 4, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 27, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 25, 2025Other filingsSEC
424B2 · ProspectusAug 22, 2025Offer documentSEC
CORRESP · Letter to the SECAug 20, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 18, 2025Other filingsSEC
8-K · Current reportAug 12, 2025Material contractSEC
S-3 · Registration statementAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
EFFECT · Notice that a registration is effectiveAug 11, 2025Other filingsSEC
CORRESP · Letter to the SECAug 6, 2025Other filingsSEC
8-K · Current reportAug 6, 2025Management or board changeSEC
UPLOAD · Letter from the SECAug 5, 2025Other filingsSEC
S-3 · Registration statementAug 1, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 30, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 30, 2025Big-stake noticeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
DJul 24, 2025Other filingsSEC
8-K · Current reportJul 21, 2025Material contractSEC
8-K · Current reportJul 17, 2025Current reportSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
8-K · Current reportMay 15, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
ARS · Annual report to shareholdersMar 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialMar 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementMar 28, 2025Meeting noticeSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
8-K · Current reportMar 17, 2025ResultsSEC
8-K · Current reportMar 6, 2025Management or board changeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 24, 2025Insider tradeSEC
8-K · Current reportFeb 24, 2025Management or board changeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportAug 7, 2024ResultsSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveJul 19, 2024Other filingsSEC
424B3 · ProspectusJul 18, 2024Offer documentSEC
CORRESP · Letter to the SECJul 16, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 15, 2024Other filingsSEC
S-3 · Registration statementJul 10, 2024Offer documentSEC
SC 13G · Big-stake noticeJul 8, 2024Big-stake noticeSEC
DJul 2, 2024Other filingsSEC
144 · Notice of proposed saleJul 2, 2024Other filingsSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
8-K · Current reportJun 26, 2024Material contractSEC
8-K · Current reportJun 26, 2024Current reportSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMay 24, 2024Offer documentSEC
8-K · Current reportMay 23, 2024Management or board changeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
8-K · Current reportApr 10, 2024Management or board changeSEC
EFFECT · Notice that a registration is effectiveApr 10, 2024Other filingsSEC
CORRESP · Letter to the SECApr 4, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 4, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 4, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 4, 2024Meeting noticeSEC
UPLOAD · Letter from the SECMar 26, 2024Other filingsSEC
S-3 · Registration statementMar 21, 2024Offer documentSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
8-K · Current reportMar 19, 2024ResultsSEC
4 · Change in ownershipJan 23, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 23, 2024Insider tradeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
4 · Change in ownershipJan 2, 2024Insider tradeSEC
4 · Change in ownershipNov 16, 2023Insider tradeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
8-K · Current reportSep 5, 2023Management or board changeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
424B3 · ProspectusJul 10, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 10, 2023Other filingsSEC
CORRESP · Letter to the SECJul 5, 2023Other filingsSEC
UPLOAD · Letter from the SECJul 5, 2023Other filingsSEC
S-3 · Registration statementJun 30, 2023Offer documentSEC
SC 13G/A · Big-stake notice, amendedJun 27, 2023Big-stake noticeSEC
DJun 27, 2023Other filingsSEC
SC 13G/A · Big-stake notice, amendedJun 27, 2023Big-stake noticeSEC
4 · Change in ownershipJun 27, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 27, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJun 23, 2023Big-stake noticeSEC
3 · Initial statement of ownershipJun 23, 2023Insider tradeSEC
8-K · Current reportJun 21, 2023Material contractSEC
8-K · Current reportJun 21, 2023Current reportSEC
8-K · Current reportJun 21, 2023Current reportSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipJun 2, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 30, 2023Insider tradeSEC
8-K · Current reportMay 30, 2023Management or board changeSEC
8-K · Current reportMay 22, 2023Current reportSEC
8-K · Current reportMay 18, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
DApr 18, 2023Other filingsSEC
4 · Change in ownershipApr 11, 2023Insider tradeSEC
3 · Initial statement of ownershipApr 11, 2023Insider tradeSEC
ARS · Annual report to shareholdersApr 4, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 4, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 4, 2023Meeting noticeSEC
10-K · Annual reportMar 28, 2023Annual reportSEC
8-K · Current reportMar 28, 2023ResultsSEC
PRE 14A · Preliminary proxy statementMar 17, 2023Meeting noticeSEC
8-K · Current reportMar 10, 2023Current reportSEC
8-K/A · Current report, amendedMar 10, 2023Management or board changeSEC
4 · Change in ownershipMar 6, 2023Insider tradeSEC
3 · Initial statement of ownershipMar 6, 2023Insider tradeSEC
8-K · Current reportMar 6, 2023Management or board changeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 13, 2023Big-stake noticeSEC
4 · Change in ownershipJan 3, 2023Insider tradeSEC
4 · Change in ownershipJan 3, 2023Insider tradeSEC

This page holds 200 of 429 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from DiaMedica Therapeutics Inc.’s releases · as of Nov 9, 2026

Common shares
53,957,474
Fully diluted
53,957,474

Fully diluted

LineSharesAs of
Common shares53,957,474Nov 9, 2026

Share count over time

CountShares
Nov 9, 202653,957,474

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Cooperman Leon G3.45M6.4%US$28.5MSep 30, 2026
BlackRock2.21M4.1%US$18.3MSep 30, 2026
Geode Capital894K1.7%US$7.39MSep 30, 2026
Vanguard836K1.5%US$6.91MSep 30, 2026
Millennium831K1.5%US$6.87MSep 30, 2026
State Street660K1.2%US$5.46MSep 30, 2026
Bleichroeder LP382K0.71%US$3.16MSep 30, 2026
Osaic Holdings, Inc.330K0.61%US$2.71MSep 30, 2026
Northern Trust326K0.60%US$2.7MSep 30, 2026
LPL Financial LLC236K0.44%US$1.95MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Goldman Sachs187K0.35%US$1.55MSep 30, 2026
Citadel185K0.34%US$1.53MSep 30, 2026
Trexquant Investment LP163K0.30%US$1.35MSep 30, 2026
BNY118K0.22%US$974KSep 30, 2026
Hurricane Capital Advisors LLC112K0.21%US$923KSep 30, 2026
Cobalt Capital Management, Inc.105K0.19%US$867KSep 30, 2026
Schwab102K0.19%US$842KSep 30, 2026
Members Wealth LLC101K0.19%US$810KSep 30, 2026
Gsa Capital Partners LLP97,0260.18%US$802KSep 30, 2026
XTX Topco Ltd82,1990.15%US$680KSep 30, 2026
Diametric Capital, LP80,9140.15%US$669KSep 30, 2026
Magnolia Capital Advisors LLC77,4050.14%US$640KSep 30, 2026
Bank of America77,3730.14%US$640KSep 30, 2026
Morgan Stanley71,0930.13%US$588KSep 30, 2026
Squarepoint Ops LLC70,6060.13%US$584KSep 30, 2026
Blue Trust, Inc.69,1220.13%US$572KSep 30, 2026
AWM Investment Company, Inc.65,0970.12%US$538KSep 30, 2026
Corient IA LP60,0000.11%US$496KSep 30, 2026
Private Capital Management, LLC60,0000.11%US$496KSep 30, 2026
Nuveen56,1210.10%US$464KSep 30, 2026
Meridian Wealth Management, LLC43,6000.08%US$361KSep 30, 2026
Ballentine Partners, LLC40,6210.08%US$336KSep 30, 2026
Tocqueville Asset Management L.P.40,2000.07%US$332KSep 30, 2026
Catalyst Financial Partners LLC38,4570.07%US$318KSep 30, 2026
Cetera Investment Advisers33,8400.06%US$280KSep 30, 2026
Creative Planning32,3810.06%US$268KSep 30, 2026
DWS31,8590.06%US$263KSep 30, 2026
T. Rowe Price30,4920.06%US$253KSep 30, 2026
Rhumbline Advisers30,0670.06%US$249KSep 30, 2026
HSBC28,8470.05%US$242KSep 30, 2026
Susquehanna24,2540.04%US$201KSep 30, 2026
AQR Capital Management LLC23,5840.04%US$195KSep 30, 2026
Invesco19,2390.04%US$159KSep 30, 2026
Barclays18,3530.03%US$152KSep 30, 2026
JPMorgan18,1530.03%US$149KSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.17,4910.03%US$145KSep 30, 2026
HighTower Advisors, LLC17,0000.03%US$141KSep 30, 2026
Fidelity16,4710.03%US$136KSep 30, 2026
Cornerstone Wealth Management, LLC16,2500.03%US$134KSep 30, 2026
Raymond James Financial Inc15,7910.03%US$131KSep 30, 2026

This page holds 50 of 92 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
iShares Russell 2000 ETF933K1.7%US$6.57MJun 30, 2026
Fidelity Small Cap Index Fund400K0.74%US$2.53MJul 31, 2026
Vanguard Extended Market Index Fund356K0.66%US$2.5MJun 30, 2026
iShares Russell 2000 Growth ETF344K0.64%US$2.42MJun 30, 2026
Vanguard Russell 2000 Index Fund177K0.33%US$1.06MMay 31, 2026
Fidelity Extended Market Index Fund159K0.29%US$951KMay 31, 2026
iShares Micro-Cap ETF123K0.23%US$866KJun 30, 2026
Schwab Small-Cap Index Fund88,3870.16%US$560KJul 31, 2026
Master Small Cap Index Series75,5660.14%US$532KJun 30, 2026
Fidelity Total Market Index Fund60,7380.11%US$364KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Jacob Discovery Fund59,7300.11%US$358KMay 31, 2026
Nuveen Small Cap Blend Index Fund48,3490.09%US$307KJul 31, 2026
Fidelity Series Total Market Index Fund46,3300.09%US$278KMay 31, 2026
Jacob Small Cap Growth Fund41,0000.08%US$246KMay 31, 2026
EQ/2000 Managed Volatility Portfolio36,4870.07%US$257KJun 30, 2026
Fidelity Small Cap Growth Index Fund34,1970.06%US$241KJun 30, 2026
Fidelity Nasdaq Composite Index Fund33,3120.06%US$200KMay 31, 2026
Vanguard Russell 2000 Growth Index Fund32,1410.06%US$193KMay 31, 2026
LVIP State Street Small-Cap Index Fund20,9000.04%US$147KJun 30, 2026
Small Cap Index Fund18,9870.04%US$134KJun 30, 2026
Global X Russell 2000 ETF17,4860.03%US$111KJul 31, 2026
Fidelity ZERO Total Market Index Fund15,8610.03%US$101KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund14,6100.03%US$103KJun 30, 2026
Small Cap Index Fund13,3300.02%US$79,847May 31, 2026
Schwab Total Stock Market Index Fund13,2510.02%US$84,011Jul 31, 2026
Small Cap Core Fund13,0970.02%US$92,203Jun 30, 2026
MetLife Russell 2000 Index Portfolio12,4350.02%US$87,542Jun 30, 2026
Fidelity ZERO Extended Market Index Fund12,1650.02%US$77,126Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio11,2000.02%US$78,848Jun 30, 2026
Siit Extended Market Index Fund9,9000.02%US$59,301May 31, 2026
Small-Cap Index Portfolio9,4400.02%US$66,458Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio9,3360.02%US$65,725Jun 30, 2026
NVIT Small Cap Index Fund8,5940.02%US$60,502Jun 30, 2026
1290 VT Micro Cap Portfolio8,2750.02%US$58,256Jun 30, 2026
VIP Disciplined Small Cap Portfolio7,2520.01%US$51,054Jun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund6,4970.01%US$45,739Jun 30, 2026
Small Cap Index Trust6,4160.01%US$45,169Jun 30, 2026
DWS Small Cap Index VIP5,7460.01%US$40,452Jun 30, 2026
T. Rowe Price Small-Cap Index Fund5,5900.01%US$39,354Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio5,5380.01%US$38,988Jun 30, 2026
iShares Total U.S. Stock Market Index Fund5,293<0.01%US$33,558Jul 31, 2026
Voya RussellTM Small Cap Index Portfolio5,168<0.01%US$36,383Jun 30, 2026
Fidelity Flex Small Cap Index Fund4,780<0.01%US$30,305Jul 31, 2026
BlackRock Small Cap Index V.I. Fund4,501<0.01%US$31,687Jun 30, 2026
SA Small Cap Index Portfolio3,540<0.01%US$22,444Jul 31, 2026
Nationwide Small Cap Index Fund3,498<0.01%US$22,177Jul 31, 2026
iShares Russell Small/Mid-Cap Index Fund3,449<0.01%US$21,867Jul 31, 2026
PD Small-Cap Growth Index Portfolio3,335<0.01%US$23,478Jun 30, 2026
SmallCap Growth Fund I3,161<0.01%US$20,041Jul 31, 2026
EQ/Small Company Index Portfolio3,140<0.01%US$22,106Jun 30, 2026

This page holds 50 of 78 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
TRILL AB16.90%8.83MDec 31, 2025Schedule 13G
TomEnterprise AB16.28%8.38MJul 23, 2025Schedule 13G
Richard Jacinto II9.60%4.96MSep 30, 2025Schedule 13G
Cooperman Leon G6.60%3.45MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Richard Kuntz
Other companies: Identiv, Inc. (Director · Since at least Oct 18, 2022); ZimVie Inc (Director · Since at least Mar 1, 2022); Rockley Photonics Holdings Ltd (Director · Aug 8, 2022 – Aug 8, 2022 · Past); Medtronic plc. (SVP & Chief Medical & Science · Jan 9, 2018 – Nov 5, 2021 · Past)
Director · Since at least May 30, 2023
Amy Burroughs
Other companies: Terns Pharmaceuticals, Inc. (Chief Executive Officer, Director · Since at least Feb 7, 2024); Tenaya Therapeutics, Inc. (Board Member · Since at least Dec 5, 2022)
Director · Jul 15, 2021 – Jan 3, 2023 · Past
Daniel O’Connor
Other companies: Ambrx Biopharma Inc. (President and CEO, Director · Jan 1, 2023 – Mar 7, 2024 · Past); ZyVersa Therapeutics, Inc. (Director · Dec 20, 2021 – Dec 12, 2022 · Past)
Director · Since at least Feb 20, 2025
James Parsons
Other companies: Oncolytics Biotech Inc. (Director · Since at least Jan 1, 2026); Trillium Therapeutics Inc (Chief Financial Officer · Jan 1, 2021 – Nov 17, 2021 · Past)
Chairman of the Board · Since at least Dec 6, 2018
Julie Krop
Other companies: Aquestive Therapeutics, Inc. (Aquestive Director, and Chief Medical Officer of DiaMedica Therapeutics, Inc. · Since at least Feb 10, 2021); AMAG Pharmaceuticals Inc (Chief Medical Officer · Jun 1, 2015 – Mar 2, 2020 · Past)
Chief Medical Officer · Since at least Aug 11, 2025
Masuoka K Lorianne
Other companies: Opiant Pharmaceuticals Inc (Director · Mar 18, 2021 – Mar 2, 2023 · Past); Marinus Pharmaceuticals Inc (Chief Medical Officer · Dec 6, 2017 – Aug 21, 2019 · Past)
Chief Medical Officer · Jan 22, 2024 – Jan 22, 2024 · Past
David Wambeke
Other companies: NeuroOne Medical Technologies Corporation (Chief Business Officer · Since at least Mar 1, 2026)
Chief Business Officer · Since at least Apr 10, 2023
Scott Kellen
Other companies: Kips Bay Medical Inc (COO, CFO, VP of Finance & Secy · Feb 10, 2011 – Mar 10, 2015 · Past)
Chief Financial Officer · Since at least Dec 6, 2018
Tanya Lewis
Other companies: Replimune Group, Inc. (Chief Dev. Op. Officer · Apr 1, 2022 – Jun 13, 2023 · Past)
Director · Since at least Mar 1, 2023
Ambarish ShahChief Technology Officer · Since at least Nov 5, 2026
All 23 people
PersonSeat
Charles SembaDirector · Since at least Jul 15, 2021
Dietrich John PaulsPresident & CEO, Director · Since at least Dec 6, 2018
Dominic CundariChief Commercial Officer · Since at least Feb 1, 2022
Harry W Alcorn JrSVP, Clinical Operations · Dec 6, 2018 – Sep 15, 2021 · Past
Julie VanOrsdel DavesSVP Clinical Development Oper. · Sep 13, 2022 – Jun 1, 2023 · Past
Kirsten L GruisChief Medical Officer · Jan 3, 2022 – Jun 1, 2023 · Past
Michael GiuffreDirector · Since at least Nov 5, 2026
Randall Michael GiuffreDirector · Since at least Dec 6, 2018
Richard D PilnikDirector · Dec 6, 2018 – Apr 7, 2025 · Past
Rick PaulsPresident & CEO · Since at least Oct 22, 2026
Sydney A GilmanVP, Regulatory Affairs · Nov 1, 2019 – Jul 28, 2021 · Past
Todd A VerdoornChief Scientific Officer · Dec 6, 2018 – Jun 24, 2019 · Past
Zhenyu XiaoDirector · Dec 6, 2018 – Jun 24, 2019 · Past

Open People

Log in to ask 6ix AI your own questions about DiaMedica Therapeutics Inc.